Merck & Company Inc (MRK)vsXOMA Royalty Corporation (XOMA)
MRK
Merck & Company Inc
$120.79
-3.46%
HEALTHCARE · Cap: $285.64B
XOMA
XOMA Royalty Corporation
$42.09
-0.73%
HEALTHCARE · Cap: $522.84M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 135351% more annual revenue ($65.77B vs $48.55M). XOMA leads profitability with a 69.6% profit margin vs 13.6%. XOMA trades at a lower P/E of 26.6x. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
XOMA
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Margin of Safety
-20.6%
Fair Value
$19.29
Current Price
$42.09
$22.80 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Keeps 70 of every $100 in revenue as profit
Earnings expanding 207.9% YoY
Every $100 of equity generates 28 in profit
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Moderate valuation
Smaller company, higher risk/reward
Elevated debt levels
Revenue declined 22.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : XOMA
The strongest argument for XOMA centers on Profit Margin, EPS Growth, Return on Equity. Profitability is solid with margins at 69.6% and operating margin at -3.9%.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : XOMA
The primary concerns for XOMA are P/E Ratio, Market Cap, Debt/Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while XOMA is a declining play — different risk/reward profiles.
XOMA carries more volatility with a beta of 0.90 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 49/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →XOMA Royalty Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and Asia Pacific. The company is headquartered in Emeryville, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?